Clinical Trials
85 trialsTARLATEM
Centre Leon Berard
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
A Study of Mirdametinib in People With Central Nervous System Tumors
Memorial Sloan Kettering Cancer Center
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
LIBRETTO-001
Eli Lilly and Company
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
ELECTRA
Stemline Therapeutics, Inc.
STARTRK-NG
Hoffmann-La Roche
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
LIBRETTO-121
Eli Lilly and Company
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
LOC-R01
Institut Curie
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
OH2 Oncolytic Viral Therapy in Central Nervous System Tumors
Binhui Biopharmaceutical Co., Ltd.
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
University Hospital Heidelberg
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
NEWEL
Helsinn Healthcare SA
MSC11FCD-GBM
CHA University
RTOG 0913
Radiation Therapy Oncology Group
Study of EZN-2208 Pediatric Patients With Solid Tumors
Enzon Pharmaceuticals, Inc.
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
University of California, San Francisco
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
National Cancer Institute (NCI)
Sirolimus in Treating Patients With Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
Northwestern University
DEND/TIA
Clinica Universidad de Navarra, Universidad de Navarra
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Alliance for Clinical Trials in Oncology
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CCI-779 in Treating Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
University of California, Davis
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
OHSU Knight Cancer Institute
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Study of D-Methadone in Patients With Chronic Pain
Memorial Sloan Kettering Cancer Center
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Memorial Sloan Kettering Cancer Center